[Early prediction of @entity16332 response in e antigen-negative chronic @entity1956 XXXX ].

@entity1 @entity97 @entity16332 @entity1956
OBJECTIVE: To evaluate the effects of ALT, HBsAg and @entity97 DNA at the baseline, 4 and 12 weeks after @entity16332 treatment on the long term (104 weeks) response in e antigen-negative chronic @entity1956 @entity1 . METHODS: 127 adult e antigen-negative chronic @entity1956 @entity1 were enrolled in this study. All @entity1 received treatment on LAM 100 mg/d for at least 104 weeks. The liver function, serum HBV markers and @entity97 viral load were regularly checked during the treatment. The effects of ALT, HBsAg and @entity97 DNA at the baseline, 4 and 12 weeks after @entity16332 treatment on the response at 104 weeks were statistically analyzed. RESULTS: The proportion of patients with serum HBV DNA less than 1000 copies / ml at 104 weeks after LAM treatment was 50.0% and 86.8% in @entity1 with baseline ALT less than 5 ULN and ALT is more than or equal to 5 ULN, respectively (P less than 0.01). In @entity1 with baseline HBsAg less than 2000 COI and HBsAg is more than or equal to 2000 COI, the proportion of patients with serum HBsAg less than 500 COI at 104 weeks after LAM treatment was 19.1% and 17.5%, respectively (P more than 0.05). the HBsAg serological conversion rates were respectively 2.1% and 2.5% , respectively (P more than 0.05), the proportion of patients with serum HBV DNA less than 1000 copies/ml was 61.7% and 67.5%, respectively (P more than 0.05). In @entity1 with baseline @entity97 DNA less than 10(6) copies/ml and @entity97 DNA is more than or equal to 10(6) copies/ml, the proportion of @entity1 with @entity97 DNA less than 1000 copies/ml were statistically different at 4 weeks and 12 weeks after treatment, however, the proportion of @entity1 with @entity97 DNA less than 1000 copies/ml at 104 weeks after LAM treatment was 62.7% and 67.1%, respectively (P more than 0.05). In @entity1 with @entity97 DNA less than 1000 copies/ml and @entity97 DNA is more than or equal to 1000 copies/ml at 4 weeks after treatment, the proportion of @entity1 with @entity97 DNA less than 1000 copies/ml at 104 weeks after LAM treatment was 70.7% and 60.9%, respectively (P more than 0.05). In @entity1 with @entity97 DNA less than 1000 copies/ml and @entity97 DNA is more than or equal to 1000 copies/ml at 12 weeks after treatment, the proportion of @entity1 with @entity97 DNA less than 1000 copies/ml at 104 weeks after treatment was 78.8% and 38.1%, respectively (P less than 0.01). CONCLUSION: e antigen negative chronic @entity1956 @entity1 with baseline ALT is more than or equal to 5 ULN and @entity97 DNA less than 1000 copies/ml at 12 weeks after treatment have better virological response at 104 weeks after LAM treatment. The baseline HBsAg and @entity97 DNA load are associated with the virological response at 104 weeks after LAM treatment.
